Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Medical Transparency:  The Turkish Case Şerif BOYACI, pharmacist Turkish Pharmacists' Association
Transperancy in determination of the price <ul><li>Two different prices:  </li></ul><ul><li>Public price </li></ul><ul><li...
Cost estimation  <ul><li>Cost estimation for public bodies </li></ul><ul><li>Global budget (will be implemented for the ye...
The right of patient to obtain drug information <ul><li>The Regulation on the Patient Rights that ensures the right of the...
The right of patient to have access to drugs <ul><li>Again, The Regulation on the Patient Rights ensures the right to acce...
Transparency and privacy <ul><li>Privacy of the patient information is guaranteed by the laws. </li></ul><ul><li>But as an...
The sustainability of pharmaceutical services <ul><li>The guarantee of the sustainability is the continuum of reimbursemen...
Upcoming SlideShare
Loading in …5
×

Medical Transparency: The Turkish Case

1,343 views

Published on

Presentation by Şerif BOYACI, pharmacist, Turkish Pharmacists' Association on Medical Transparency: The Turkish Case, during the 69th FIP Congress, Istanbul, September 2009.

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

Medical Transparency: The Turkish Case

  1. 1. Medical Transparency: The Turkish Case Şerif BOYACI, pharmacist Turkish Pharmacists' Association
  2. 2. Transperancy in determination of the price <ul><li>Two different prices: </li></ul><ul><li>Public price </li></ul><ul><li>Retail price </li></ul><ul><li>Strict regulations in determination of public price: </li></ul><ul><li>The cheapest of reference countries </li></ul><ul><li>The cheapest within the theraupatic class. </li></ul><ul><li>Positive list </li></ul><ul><li>Co-payment of patient. </li></ul><ul><li>Retail price: </li></ul><ul><li>Fixed margin rates for wholesalers and pharmacists </li></ul>
  3. 3. Cost estimation <ul><li>Cost estimation for public bodies </li></ul><ul><li>Global budget (will be implemented for the year 2009) </li></ul><ul><li>Cost estimation of the patient </li></ul><ul><li>Standard co-payment as a tool for awareness of the drug prices </li></ul><ul><li>Extra payment for the drugs exceeding the reimbursement limit. </li></ul>
  4. 4. The right of patient to obtain drug information <ul><li>The Regulation on the Patient Rights that ensures the right of the patient to access the drug information . </li></ul><ul><li>“ Short drug information” available via website of Ministry of Health. </li></ul><ul><li>The counselling services of the pharmacists. </li></ul>
  5. 5. The right of patient to have access to drugs <ul><li>Again, The Regulation on the Patient Rights ensures the right to access the drugs. </li></ul><ul><li>The General Social Insurance System, subsumes all the citizens and non-citizens </li></ul><ul><li>The extensiveness of the pharmacies is guaranteeing the access. </li></ul>
  6. 6. Transparency and privacy <ul><li>Privacy of the patient information is guaranteed by the laws. </li></ul><ul><li>But as an implementation of e-health systems, the Smartcard application is planned to be started at January 2010, on which we have doubts about the security of the patient information. </li></ul>
  7. 7. The sustainability of pharmaceutical services <ul><li>The guarantee of the sustainability is the continuum of reimbursement system. </li></ul><ul><li>Turkey is the third most hit country by the global economic crisis. </li></ul><ul><li>Social security expenses are already exceeding the budget. </li></ul><ul><li>By generalisation of the social security system, the Institution pays the contribution of the unemployed (whose number reaches the 14.5% of the population), people below the age of 18, and people with low income. </li></ul>

×